A use of beta-glucan in order to increase anti-tumor immunity in remission after the treatment of solid tumors, where after the long-term peroral usage the concentration of the CD8+ Lymphocytes, CD19+ lymphocytes increases and the level of IgG3, IgA, CD16+56+ increases. The clinical study has shown the efficiency of the preventive treatment during the immunosensitive cancer such as breast cancer. In the preferable arrangement beta-glucan is fungal β (1,3/1,6) glucan prepared from the oyster mushroom. During the sequential usage in the first phase a high dose of beta-glucan is used and in the second phase a low dose of beta-glucan is used. The high dose of beta-glucan is at least twice the low dose of beta-glucan. The administration is long-term and continuous without sequences where the dosage is completely omitted. The daily high dose of beta-glucan range from 600 mg to 800 mg.

A use of beta-glucan in order to increase anti-tumor immunity in remission after the treatment of solid tumors, where after the long-term peroral usage the concentration of the CD8+ Lymphocytes, CD19+ lymphocytes increases and the level of IgG3, IgA, CD16+56+ increases. The clinical study has shown the efficiency of the preventive treatment during the immunosensitive cancer such as breast cancer. In the preferable arrangement beta-glucan is fungal β (1,3/1,6) glucan prepared from the oyster mushroom. During the sequential usage in the first phase a high dose of beta-glucan is used and in the second phase a low dose of beta-glucan is used. The high dose of beta-glucan is at least twice the low dose of beta-glucan. The administration is long-term and continuous without sequences where the dosage is completely omitted. The daily high dose of beta-glucan range from 600 mg to 800 mg.

The present disclosure relates to compositions comprising dietary fibers. For example, in some embodiments, the composition comprises two or more fibers (e.g., fibers such as beta-glucan, wheat dextrin, inulin, pectin, psyllium, or potato starch) each present in amount of about 40% to about 60% w/w of the composition. In some embodiments, the composition further includes a sweetener and/or a flavoring agent. Such compositions are useful in the treatment or improvement of gastrointestinal diseases.

The present disclosure relates to compositions comprising dietary fibers. For example, in some embodiments, the composition comprises two or more fibers (e.g., fibers such as beta-glucan, wheat dextrin, inulin, pectin, psyllium, or potato starch) each present in amount of about 40% to about 60% w/w of the composition. In some embodiments, the composition further includes a sweetener and/or a flavoring agent. Such compositions are useful in the treatment or improvement of gastrointestinal diseases.

The present application refers to oral compositions comprising an effective amount of a Pediococcus acidilactici strain for use in regulating blood glucose levels, as well as for the prevention and/or treatment of hyperglycemia and/or a hyperglycemia-related condition. The application also refers to Pediococcus acidilactici CECT 9879, Pediococcus acidilactici CECT 9889 and Pediococcus acidilactici CECT 9967, and to these strains for use as probiotics, medicaments and for regulating blood glucose levels, as well as for the prevention and/or treatment of hyperglycemia and/or a hyperglycemia-related condition.

The present application refers to oral compositions comprising an effective amount of a Pediococcus acidilactici strain for use in regulating blood glucose levels, as well as for the prevention and/or treatment of hyperglycemia and/or a hyperglycemia-related condition. The application also refers to Pediococcus acidilactici CECT 9879, Pediococcus acidilactici CECT 9889 and Pediococcus acidilactici CECT 9967, and to these strains for use as probiotics, medicaments and for regulating blood glucose levels, as well as for the prevention and/or treatment of hyperglycemia and/or a hyperglycemia-related condition.

A method of reducing systemic chronic inflammation in a subject by administering a composition capable of reducing the expression level of inflammatory biomarkers.

A method of reducing systemic chronic inflammation in a subject by administering a composition capable of reducing the expression level of inflammatory biomarkers.

A method of reducing systemic chronic inflammation in a subject by administering a composition capable of reducing the expression level of inflammatory biomarkers.

The present invention provides an antioxidant, an ROS inhibitor, an antioxidant enzyme production promoter, an antioxidant cosmetic, a UV care cosmetic, a prophylactic or therapeutic agent for gastrointestinal tract inflammation, and an antioxidant food or beverage, each containing an enzymatically synthesized glycogen (ESG) or an α-amylase digest (RG) thereof, as well as use for enhancing an antioxidative effect in vivo.